Eli Lilly is acquiring Adverum Biotechnologies in a deal valued at up to US$12.47 per share (roughly US$262 million) to gain control of Adverum’s lead gene therapy candidate, Ixo-vec, which is designed as a single-administration treatment for wet age-related macular degeneration (wAMD).
Glimpse:
Adverum’s candidate, Ixo-vec, is in a Phase 3 trial and aims to reduce or eliminate the burdens of frequent anti-VEGF injections in wAMD. Lilly’s acquisition brings this programme into its gene-therapy and ophthalmology portfolio, with the deal expected to close in Q4 2025.
Eli Lilly and Company has entered into a definitive agreement to acquire Adverum Biotechnologies, a clinical-stage gene therapy company focused on intravitreal, single-administration treatments for ocular disease. The lead candidate in the transaction is Ixo-vec (also known by its technical name ixoberogene soroparvovec), currently being evaluated in a Phase 3 clinical trial (ARTEMIS) for wet age-related macular degeneration (wAMD).
Under the terms of the agreement, Lilly will launch a tender offer to purchase all outstanding shares of Adverum common stock for US$3.56 per share in cash at closing, plus one contingent value right (CVR) per share that may pay up to an additional US$8.91 if certain milestones are achieved. This brings the potential total per share consideration up to US$12.47.
The CVR milestones include: (1) up to US$1.78 per CVR if Ixo-vec obtains U.S. regulatory approval within seven years of closing; and (2) up to US$7.13 per CVR if Ixo-vec’s annual worldwide net sales exceed US$1 billion within ten years of closing.
For such a deal to close, the transaction is subject to customary closing conditions including the tender of a majority of outstanding Adverum shares. The companies expect the acquisition to close in the fourth quarter of 2025.
Ixo-vec is noteworthy because it is designed to deliver long-term intraocular levels of aflibercept (an anti-VEGF agent) via a one-time intravitreal injection, potentially shifting the treatment paradigm for wet AMD away from repeated injections every few weeks. The programme has received regulatory designations including Fast Track and RMAT from the U.S. FDA, PRIME from the EMA and an Innovation Passport from the UK-MHRA.
This acquisition aligns with Lilly’s strategic focus on gene therapies and long-acting treatments for age-related conditions. By bringing Adverum’s platform and Ixo-vec into its portfolio, Lilly is entering the ophthalmology market more deeply and positioning for growth in one of the high-prevalence retinal disease segments. Analysts note that if approved, Ixo-vec could reach blockbuster status given the global burden of wet AMD and the current standard of care’s frequent treatment burden.
“Ixo-vec has the potential to transform wAMD treatment from a paradigm of chronic care with repeated intravitreal injections to a convenient one-time therapy.”
By
HB Team
